TY - JOUR T1 - No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic JF - bioRxiv DO - 10.1101/2020.07.30.228213 SP - 2020.07.30.228213 AU - Julia Schwaiger AU - Michael Karbiener AU - Claudia Aberham AU - Maria R. Farcet AU - Thomas R. Kreil Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/07/30/2020.07.30.228213.abstract N2 - The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing antibodies to the new species in humans is unclear. The question is of particular relevance for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 IVIG preparations, produced from plasma collected in Europe and the US, highly potent neutralization of a seasonal coronavirus was confirmed, yet no cross-neutralization of the new SARS-CoV-2 was seen.SUMMARY IVIG products manufactured from pre-pandemic plasma do not neutralize SARS-CoV-2 but contain high neutralizing titers for seasonal coronavirus hCoV-229E.Competing Interest StatementAuthors are employees of Baxter AG, now part of the Takeda group of companies, Vienna, Austria. MK, CA, MRF and TRK have Takeda stock interest. ER -